IL2 and cancer: Moreover, high‐dose IL‐2 administration is associated with severe side effects, including the vascular leak syndrome, as observed in cancer patients treated by IL‐2‐based immunotherapy.[45, 46] Physical contact between T and NK cells provides a localized environment where NK cells can receive high concentrations of IL‐2 without affecting the neighboring non‐target cells.